Livzon Pharmaceutical Group Inc.
Livzon Pharmaceutical Group Co., Ltd. is a comprehensive enterprise group integrating pharmaceutical research and development, production and sales. It was founded in January 1985 with registered capital of RMB 390 million. Group now has 18 patented products, 21 exclusive products, including Shenqi Fuzheng injection and Ai Purazi has won the Guangdong Provincial Science and Technology Progress Award. In January 2016, the Group of the original research drug Eppoprazole has won the national scientific and technological progress second prize award.
In recent years, the company has won a number of domestic industry honor: 2011 was named China's most competitive pharmaceutical listed companies 20, in 2012 was named the best listed corporate governance 10; 2013 was named listed companies investment The value of TOP10 strong, 2014 - 2015 was named China 's top 500 brand value of the enterprise.
Lizhu is the top 50 Chinese medicine, the national technological innovation demonstration enterprises. 2014 completed B to H shares, the industry's first. In 2016, the Group will be relocated to Jinzhu District Livzon Industrial Park, Livzon Industrial Park covers an area of 427,000 square meters, with a total investment of about 20 billion yuan, according to the US FDA and the EU standard construction of world-class modern pharmaceutical production base.
The company is committed to the cause of human health, to provide the leading domestic and world-class characteristics of specialist medicine, the company is committed to the strategic transformation of bio-pharmaceuticals, open up the layout of "precision medical" field! According to the company's development strategy to 2017 will achieve sales targets 10 billion target.
